Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | YAP1 | P46937 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306376 | 0.90 | JAK2 (0.46) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL306377 | 0.90 | JAK2 (0.46) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL969537 | 0.90 | JAK2 (0.46) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL20564800 | 0.85 | MEN1 (0.45) | SMN1; SMN2LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL5717213 | 0.84 | KDM4E (0.59) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL30987068 | 0.83 | JAK2 (0.47) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL30987030 | 0.82 | GAA (0.41) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL30987040 | 0.82 | GAA (0.41) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL16643747 | 0.81 | JAK2 (0.48) | SMN1; SMN2STSGAATHRBGPR119 | |
| SCHEMBL20626607 | 0.81 | JAK2 (0.48) | SMN1; SMN2STSGAATHRBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. | 2025-03-06 | — | — | US | disclosed |
| CN-119285572-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119264073-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-110913858-B | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2022159644-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2022-02-10 | — | — | US | disclosed |
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-110913858-A | Kinase inhibitors and uses thereof | 戴纳立制药公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-03 | — | — | US | disclosed |
| US-20180339971-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2018-11-29 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-10071974-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-09-11 | — | — | US | disclosed |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-09 | — | — | US | disclosed |
| EP-3218372-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075240-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10071974-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | SMN1; SMN2 875/4885STS 545/4885GAA 2266/4885 |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | SMN1; SMN2 3852/4885STS 2886/4885GAA 1988/4885 |
| US-20180339971-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | SMN1; SMN2 875/4885STS 545/4885GAA 2266/4885 |
| US-20170320838-A1 | MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR1, SSTR3 | SMN1; SMN2 875/4885STS 545/4885GAA 2266/4885 |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | SMN1; SMN2 3852/4885STS 2886/4885GAA 1988/4885 |
| US-10577336-B2 | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR1, SSTR3 | SMN1; SMN2 875/4885STS 545/4885GAA 2266/4885 |
| US-20250073340-A1 | SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF | FOXM1, MDM2, FOXO1 | SMN1; SMN2 1925/4885STS 1117/4885GAA 3353/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | SMN1; SMN2 2441/4885STS 1624/4885GAA 3215/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | SMN1; SMN2 3852/4885STS 2886/4885GAA 1988/4885 |
| US-20220041620-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | SMN1; SMN2 3852/4885STS 2886/4885GAA 1988/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | SMN1; SMN2 3852/4885STS 2886/4885GAA 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.